BioCardia (BCDA) CEO Peter Altman Buys $768 of Stock
Peter Altman, CEO of BCDA, purchased 800 shares at $0.96 each on June 18, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Peter Altman, President and CEO at BioCardia, Inc. ($BCDA), bought 800 shares at an average price of $0.96, worth about $768, on June 18, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $BCDA is up 12.4% after 1 week, down 7.2% after 1 month and down 5.2% to date (from the $0.97 close on Jun 18, 2026).
BCDA
BioCardia, Inc.
Key Points
- Peter Altman, CEO of BCDA, bought 800 shares at $0.96 per share on June 18, 2026.
- Shares of BCDA traded near $0.97 on Monday, with notable institutional interest from firms like Vanguard and Geode Capital.
- HC Wainwright & Co. reiterated its buy rating on BCDA with a $25 price target on June 9, 2026.
Get $BCDA trade alerts by text
We text you when insiders, Congress or big funds trade $BCDA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated BioCardia, Inc. alert may contain errors. Disclosures
Peter Altman, the President and CEO of BCDA, purchased 800 shares of the company at an average price of $0.96 on June 18, 2026. This insider buying follows a series of recent acquisitions by Altman, highlighting his ongoing confidence in the company's prospects.
Insider Buying and Selling at BioCardia, Inc.
Peter Altman has been actively buying shares of BCDA. On June 18, 2026, he bought 800 shares at $0.96 each, adding to his previous purchases of 1,500 shares at $0.85 on June 17, 2026, and 5,000 shares at $0.85 on June 9, 2026. These transactions were not part of a pre-arranged trading plan, indicating his proactive investment approach.
Other Institutional Activity in BCDA
Institutional investors have shown varied interest in BCDA. Vanguard Capital Management LLC opened a new position with 124,591 shares valued at about $150,755. Geode Capital Management, LLC increased its holdings by 28,284 shares, now holding 94,287 shares worth approximately $114,086, marking a 42.9% increase. Conversely, Citadel Advisors LLC reduced its stake by 30,863 shares, ending with 63,384 shares valued at $76,695, a 32.7% decrease.
BioCardia, Inc. Stock Down 17.1%
Shares of BCDA traded near $0.97 on Monday. The company has attracted attention from both insiders and institutional investors. While specific financial metrics were not provided, the stock's recent insider and institutional activities suggest ongoing interest and potential future developments.
Analysts Set New Price Targets
On June 9, 2026, HC Wainwright & Co. reiterated its buy rating for BCDA with a price target of $25. This reflects continued confidence from analysts in the company's future performance.
Bottom Line
Peter Altman's recent share purchases add to a pattern of insider confidence in BCDA. Institutional investors have also shown varied interest, with some increasing their stakes significantly. Analysts at HC Wainwright & Co. maintain a positive outlook on the stock, reinforcing its potential in the market.
Related Filing Alerts
Source: Peter Altman's Form 4 filing on $BCDA (Jun 18, 2026). Find the original filing: BCDA Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts